|Description||Lucitanib, also known as E-3810, is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. VEGFR/FGFR dual kinase inhibitor E-3810 inhibits VEGFR-1, -2, -3 and FGFR-1, -2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and FGFRs belong to the family of receptor tyrosine kinases that may be upregulated in various tumor cell types.|
|Synonyms||E-3810; E3810; E 3810; Lucitanib.|
|Current Developer||Ethical Oncology Science|
BLU-554 is a potent and selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) (IC50 = 5 nM), which is promisingly to be used for the treatment of h...
H3B-6527 is a potent, highly selective and orally active FGFR4 inhibitor with potential antineoplastic activity.
Potent and selective inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases 1, 2, 3 and 4 (with IC50 values of 0.9, 1.4, 1.0 and 60 nM for FGFR1...
BGJ398, also known as NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs...
FGFR4-IN-1 is a potent and selective FGFR4 inhibitor with potential for the treatment of gastric cancer.
Dovitinib, also referred as CHIR-258 or TKI258, is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R, c-KIT, ...
SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth...
NSC12 is an extracellular trap for fibroblast growth factor 2 (FGF2). It binds FGF2 with Kd value of 51 µM and interferes with its interaction with FGFR1 withou...
PD173074 is a small-molecule FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines. PD173074 suppressed cell prol...
BIBF 1120 esylate
Nintedanib esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
ACTB-1003 is an oral kinase inhibitor with multiple modes of action, targeting cancer mutations via FGFR inhibition FGFR1, angiogenesis through inhibition of VE...
ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation ...
Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and ...
BLU9931 is a potent and irreversible small-molecule inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 si...
This active molecular is a Axl receptor tyrosine kinase inhibitor, Proto oncogene protein c met inhibitor, Type-1, Type-2 and Type-3 fibroblast growth factor re...
FGF-401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4) (IC50= 1.9 nM) developed for the treatment of solid tumor.
Heparan sulfate, a complex and linear polysaccharide in which the backbone is composed of repeating sulfated disaccharide units, exists as part of glycoproteins...
SSR128129E free acid
SSR128129E free acid is a multi-FGFR blocker with allosteric properties. It inhibits FGFR signaling by binding to the extracellular FGFR domain without affectin...
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59...
Erdafitinib, also known as JNJ-42756493, is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential an...